{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:00:58Z","timestamp":1794852058395,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50802-2","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:02:25Z","timestamp":1722942145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, immunogenicity and safety of CoronaVac\u00ae in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Qianqian","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck-Hock","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-8742","authenticated-orcid":false,"given":"Gang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"50802_CR1","unstructured":"WHO. Interim statement on COVID-19 vaccination for children and adolescents, 2021. World Health Organization, Geneva https:\/\/www.who.int\/news\/item\/24-11-2021-interim-statement-on-covid-19-vaccination-for-children-and-adolescents."},{"key":"50802_CR2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/jmv.26398","volume":"93","author":"X Cui","year":"2021","unstructured":"Cui, X. et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J. Med Virol. 93, 1057\u20131069 (2021).","journal-title":"J. Med Virol."},{"key":"50802_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijid.2020.06.014","volume":"97","author":"R Ebina-Shibuya","year":"2020","unstructured":"Ebina-Shibuya, R., Namkoong, H., Shibuya, Y. & Horita, N. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases. Int J. Infect. Dis. 97, 371\u2013373 (2020).","journal-title":"Int J. Infect. Dis."},{"key":"50802_CR4","first-page":"51","volume":"38","author":"T Radia","year":"2021","unstructured":"Radia, T. et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr. Respir. Rev. 38, 51\u201357 (2021).","journal-title":"Paediatr. Respir. Rev."},{"key":"50802_CR5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jama.2021.2091","volume":"325","author":"LR Feldstein","year":"2021","unstructured":"Feldstein, L. R. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325, 1074\u20131087 (2021).","journal-title":"JAMA"},{"key":"50802_CR6","doi-asserted-by":"publisher","unstructured":"Engzell, P., Frey, A., Verhagen, M. D. Learning loss due to school closures during the COVID-19 pandemic. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2022376118 (2021).","DOI":"10.1073\/pnas.2022376118"},{"key":"50802_CR7","doi-asserted-by":"publisher","first-page":"106349","DOI":"10.1016\/j.ypmed.2020.106349","volume":"143","author":"R L\u00f3pez-Bueno","year":"2021","unstructured":"L\u00f3pez-Bueno, R. et al. Potential health-related behaviors for pre-school and school-aged children during COVID-19 lockdown: a narrative review. Prev. Med. 143, 106349 (2021).","journal-title":"Prev. Med."},{"key":"50802_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10540-2","volume":"21","author":"SL McKune","year":"2021","unstructured":"McKune, S. L. et al. Psychosocial health of school-aged children during the initial COVID-19 safer-at-home school mandates in Florida: a cross-sectional study. BMC Public Health 21, 603 (2021).","journal-title":"BMC Public Health"},{"key":"50802_CR9","doi-asserted-by":"publisher","first-page":"e0242587","DOI":"10.1371\/journal.pone.0242587","volume":"16","author":"B Rumain","year":"2021","unstructured":"Rumain, B., Schneiderman, M. & Geliebter, A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. PLoS ONE 16, e0242587 (2021).","journal-title":"PLoS ONE"},{"key":"50802_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamapediatrics.2021.2770","volume":"175","author":"LA Paul","year":"2021","unstructured":"Paul, L. A. et al. Association of age and pediatric household transmission of SARS-CoV-2 Infection. JAMA Pediatr. 175, 1151\u20131158 (2021).","journal-title":"JAMA Pediatr."},{"key":"50802_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","volume":"387","author":"EJ Anderson","year":"2022","unstructured":"Anderson, E. J. et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N. Engl. J. Med. 387, 1673\u20131687 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50802_CR12","doi-asserted-by":"publisher","unstructured":"Gunale B., et al. Safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in children and adolescents in India: a phase 2-3 randomized clinical trial. JAMA Pediatr. https:\/\/doi.org\/10.1001\/jamapediatrics.2023.2552 (2023).","DOI":"10.1001\/jamapediatrics.2023.2552"},{"key":"50802_CR13","doi-asserted-by":"publisher","first-page":"e239135","DOI":"10.1001\/jamanetworkopen.2023.9135","volume":"6","author":"G \u00c1\u00f1ez","year":"2023","unstructured":"\u00c1\u00f1ez, G. et al. Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial. JAMA Netw. Open 6, e239135 (2023).","journal-title":"JAMA Netw. Open"},{"key":"50802_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"50802_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 803\u2013812 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"50802_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","volume":"21","author":"B Han","year":"2021","unstructured":"Han, B. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 1645\u20131653 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"50802_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213\u2013222 (2021).","journal-title":"Lancet"},{"key":"50802_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04775-4","volume":"21","author":"R Palacios","year":"2020","unstructured":"Palacios, R. et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials 21, 853 (2020).","journal-title":"Trials"},{"key":"50802_CR19","unstructured":"WHO. Prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control), 2021. https:\/\/extranet.who.int\/pqweb\/vaccines\/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-CoronaVac."},{"key":"50802_CR20","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","volume":"39","author":"E Fadlyana","year":"2021","unstructured":"Fadlyana, E. et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine 39, 6520\u20136528 (2021).","journal-title":"Vaccine"},{"key":"50802_CR21","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 22, 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"50802_CR22","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50802_CR23","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/jmv.27697","volume":"94","author":"S Chenchula","year":"2022","unstructured":"Chenchula, S., Karunakaran, P., Sharma, S. & Chavan, M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J. Med. Virol. 94, 2969\u20132976 (2022).","journal-title":"J. Med. Virol."},{"key":"50802_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","volume":"7","author":"M Li","year":"2022","unstructured":"Li, M. et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct. Target Ther. 7, 146 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"50802_CR25","doi-asserted-by":"publisher","first-page":"e28138","DOI":"10.1002\/jmv.28138","volume":"95","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Zhi, H. & Teng, Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J. Med. Virol. 95, e28138 (2023).","journal-title":"J. Med. Virol."},{"key":"50802_CR26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41591-022-01874-4","volume":"28","author":"A Jara","year":"2022","unstructured":"Jara, A. et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat. Med. 28, 1377\u20131380 (2022).","journal-title":"Nat. Med."},{"key":"50802_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32524-5","volume":"13","author":"PTV Florentino","year":"2022","unstructured":"Florentino, P. T. V. et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nat. Commun. 13, 4756 (2022).","journal-title":"Nat. Commun."},{"key":"50802_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa2211031","volume":"388","author":"FM Mu\u00f1oz","year":"2023","unstructured":"Mu\u00f1oz, F. M. et al. Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age. N. Engl. J. Med. 388, 621\u2013634 (2023).","journal-title":"N. Engl. J. Med."},{"key":"50802_CR29","unstructured":"HQ WHO. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States. https:\/\/www.who.int\/ (2021)."},{"key":"50802_CR30","unstructured":"Standardization WECoB. WHO Guidelines on Non-clinical Evaluation of Vaccines. Tech. Rep. Ser. 927 (WHO 2005)."},{"key":"50802_CR31","unstructured":"Administration. CNMP. Guidelines for grading standards of adverse events in clinical trials of preventive vaccines (accessed 29 March 2020) https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20191231111901460.html."},{"key":"50802_CR32","first-page":"321","volume":"13","author":"China NHCotPsRo.","year":"2020","unstructured":"China NHCotPsRo. Diagnosis and treatment plan for COVID-19 (trial version 8). Chin. J. Clin. Infect. Dis. 13, 321\u2013328 (2020).","journal-title":"Chin. J. Clin. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50802-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:02:32Z","timestamp":1722942152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50802-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50802"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50802-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.X., Y.Y., and J.Y. are employees of Sinovac Life Sciences Co., Ltd. X.M., H.Z., and G.Z. are the employees of Sinovac Biotech Co., Ltd. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6660"}}